Avapritinib Earns FDA Approval For Advanced Systemic Mastocytosis, Including Mast Cell Leukemia

Avapritinib is now fully approved to treated advanced systemic mastocytosis, according to phase 1 and phase 2 clinical trial data.

Read the full article here

Related Articles